Disruption of the KLHL37–N-Myc complex restores N-Myc degradation and arrests neuroblastoma growth in mouse models
Journal of Clinical Investigation · 2025
DOI: 10.1172/jci176655 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Investigation, 2025. Verfasst von Senfeng Xiang und 15 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Pharmacology and Toxicology, Zhejiang Province Key Laboratory of Anti-Cancer Drug Research, College of Pharmaceutical Sciences, Zhejiang…. Hauptthemen laut MEDLINE: Neuroblastoma, N-Myc Proto-Oncogene Protein, Proteolysis. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 60 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Zhejiang Provincial Natural Science Foundation of China, Natural Science Fund for Distinguished Young Scholars of Zhejiang Province.
Abstract (Originalsprache)
The N-Myc gene MYCN amplification accounts for the most common genetic aberration in neuroblastoma and strongly predicts the aggressive progression and poor clinical prognosis. However, clinically effective therapies that directly target N-Myc activity are limited. N-Myc is a transcription factor, and its stability is tightly controlled by ubiquitination-dependent proteasomal degradation. Here, we discovered that Kelch-like protein 37 (KLHL37) played a crucial role in enhancing the protein stability of N-Myc in neuroblastoma. KLHL37 directly interacted with N-Myc to disrupt N-Myc–FBXW7 interaction, thereby stabilizing N-Myc and enabling tumor progression. Suppressing KLHL37 effectively induced the degradation of N-Myc and had a profound inhibitory effect on the growth of MYCN -amplified neuroblastoma. Notably, we identified RTA-408 as an inhibitor of KLHL37 to disrupt the KLHL37–N-Myc complex, promoting the degradation of N-Myc and suppressing neuroblastoma in vivo and in vitro. Moreover, we elucidated the therapeutic potential of RTA-408 for neuroblastoma using patient-derived neuroblastoma cell and patient-derived xenograft tumor models. RTA408’s antitumor effects may not occur exclusively via KLHL37, and specific KLHL37 inhibitors are expected to be developed in the future. These findings not only uncover the biological function of KLHL37 in regulating N-Myc stability, but also indicate that KLHL37 inhibition is a promising therapeutic regimen for neuroblastoma, especially in patients with MYCN -amplified tumors.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute of Pharmacology and Toxicology, Zhejiang Province Key Laboratory of Anti-Cancer Drug Research, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, China.
- Nanhu Brain-Computer Interface Institute, Hangzhou, China.
- Children's Hospital, Zhejiang University School of Medicine, National Clinical Research Center for Child Health, Hangzhou, China.
- Engineering Research Center of Innovative Anticancer Drugs, Ministry of Education, Hangzhou, China.
- School of Medicine, Hangzhou City University, Hangzhou, China.
Förderung
- National Natural Science Foundation of China
- Zhejiang Provincial Natural Science Foundation of China
- Natural Science Fund for Distinguished Young Scholars of Zhejiang Province
Zitieren
APA
Xiang, S., Chen, P., Shi, X., Cai, H., Shen, Z., Liu, L., Xu, A., Zhang, J., Zhang, X., Bing, S., Wang, J., Shao, X., Cao, J., Yang, B., He, Q., & Ying, M. (2025). Disruption of the KLHL37–N-Myc complex restores N-Myc degradation and arrests neuroblastoma growth in mouse models. Journal of Clinical Investigation. https://doi.org/10.1172/jci176655
Vancouver
Xiang S, Chen P, Shi X, Cai H, Shen Z, Liu L, et al. Disruption of the KLHL37–N-Myc complex restores N-Myc degradation and arrests neuroblastoma growth in mouse models. Journal of Clinical Investigation. 2025. doi:10.1172/jci176655
BibTeX
@article{Xiang2025,
author = {Xiang, Senfeng and Chen, Pengfei and Shi, Xiaoxian and Cai, Hanqi and Shen, Zihan and Liu, Luyang and Xu, Aixiao and Zhang, Jianhua and Zhang, Xingya and Bing, Shaowei and Wang, Jinhu and Shao, Xuejing and Cao, Ji and Yang, Bo and He, Qiaojun and Ying, Meidan},
title = {Disruption of the KLHL37–N-Myc complex restores N-Myc degradation and arrests neuroblastoma growth in mouse models},
journal = {Journal of Clinical Investigation},
year = {2025},
doi = {10.1172/jci176655}
}
EUVIMED